Evotec SE, a life science company, Boehringer Ingelheim, a research-driven biopharmaceutical company, and bioMérieux, a world leader in in vitro diagnostics, have formed a joint venture to create the next generation of antimicrobials along with actionable diagnostics to fight Antimicrobial Resistance (AMR). The resulting company, Aurobac Therapeutics SAS, will combine the capabilities of the three founding companies towards developing a new precision medicine approach, from diagnosis to cure....